| Literature DB >> 33912615 |
Anis Jellad1, Amine Kalai1, Mohamed Guedria1, Mahbouba Jguirim2, Sana Elmhamdi3, Sana Salah1, Zohra Ben Salah Frih1.
Abstract
BACKGROUND: Active rehabilitation has an important role in the management of patellofemoral pain syndrome (PFPS). Although some studies have shown the benefit of hip-muscle strengthening, the effect of combining hip-muscle stretching with strengthening has not yet been defined.Entities:
Keywords: hip; muscle; patellofemoral pain syndrome; rehabilitation
Year: 2021 PMID: 33912615 PMCID: PMC8050763 DOI: 10.1177/2325967121989729
Source DB: PubMed Journal: Orthop J Sports Med ISSN: 2325-9671
Figure 1.Flowchart of the study. PFPS, patellofemoral pain syndrome.
Baseline Characteristics
| AB Group | BA Group | All |
| |
|---|---|---|---|---|
| Demographic characteristics | ||||
| Age, y | 32.0 ± 10.9 | 31.1 ± 10.9 | 31.6 ± 10.8 | .97 |
| Female sex, % | 73.1 | 61.9 | 68.8 | .28 |
| Body mass index, kg/m2 | 24.5 ± 4.6 | 25.4 ± 4.6 | 24.9 ± 4.3 | .22 |
| Clinical characteristics | ||||
| VAS score (0-100) | 58.0 ± 17.1 | 55.0 ± 20.6 | 56.8 ± 18.5 | .42 |
| Kujala score (0-100) | 56.7 ± 9.5 | 58.0 ± 10.4 | 57.2 ± 9.8 | .89 |
| FIQ score (0-16) | 8.3 ± 1.9 | 8.6 ± 1.9 | 8.4 ± 1.9 | .69 |
Data are reported as mean ± SD unless otherwise indicated. FIQ, Functional Index Questionnaire; VAS, visual analog scale.
Changes in Pain and Functional Scores
| Baseline | End of First Protocol |
| End of Second Protocol |
| 3 mo After End of Second Protocol |
| |
|---|---|---|---|---|---|---|---|
| AB group | |||||||
| VAS score | 58.0 ± 17.1 | 41.7 ± 17.0 | <.001 | 17.9 ± 12.1 | .01 | 9.4 ± 7.2 | .02 |
| Kujala score | 56.7 ± 9.5 | 62.8 ± 8.6 | <.001 | 75.8 ± 7.1 | <.001 | 84.0 ± 6.6 | <.001 |
| FIQ score | 8.3 ± 1.9 | 9.6 ± 1.8 | <.001 | 11.9 ± 1.3 | <.001 | 13.1 ± 1.2 | .03 |
| BA group | |||||||
| VAS score | 55.0 ± 20.6 | 22.4 ± 19.5 | .006 | 13.6 ± 11.8 | .01 | 8.2 ± 9.3 | .046 |
| Kujala score | 58.0 ± 10.4 | 62.8 ± 8.6 | <.001 | 77.9 ± 8.2 | <.001 | 84.8 ± 6.6 | .01 |
| FIQ score | 8.6 ± 1.9 | 10.8 ± 1.9 | <.001 | 12.1 ± 1.8 | <.001 | 13.1 ± 1.2 | <.001 |
Data are reported as mean ± SD. P 1: baseline vs end of first protocol; P 2: baseline vs end of second protocol; and P 3: baseline vs 3 months after end of second protocol. ES, effect size; FIQ, Functional Index Questionnaire; VAS, visual analog scale.
Improvement in Pain and Function
| Baseline to End of First Protocol | End of First Protocol to End of Second Protocol | Baseline to 3 mo After End of Second Protocol | |
|---|---|---|---|
| Protocol A | AB Group (n = 67) | BA Group (n = 42) | All (N = 109) |
| VAS score | 16.2 ± 13.0 | 8.9 ± 14.7 | 13.4 ± 14.1 |
| Kujala score | 6.3 ± 4.5 | 7.3 ± 4.0 | 6.7 ± 4.3 |
| FIQ score | 1.4 ± 0.9 | 1.4 ± 0.9 | 1.4 ± 0.9 |
| Protocol B | BA Group (n = 42) | AB Group (n = 67) | All (N = 109) |
| VAS score | 34.3 ± 18.3 | 24.3 ± 14.9 | 27.4 ± 15.7 |
| Kujala score | 12.6 ± 6.7 | 13.0 ± 5.6 | 12.9 ± 6.0 |
| FIQ score | 2.3 ± 1.1 | 2.3 ± 1.0 | 2.3 ± 1.1 |
|
| |||
| VAS score | <.001 (1.140) | <.001 (1.040) | <.001 (0.938) |
| Kujala score | <.001 (1.103) | <.001 (1.171) | <.001 (1.187) |
| FIQ score | <.001 (0.895) | <.001 (0.969) | <.001 (0.895) |
Data are reported as mean ± SD. ES, effect size; FIQ, Functional Index Questionnaire; VAS, visual analog scale.